<unk>  is an antimalarial that is FDA approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.   Common adverse reactions include dizziness, nausea, vomiting, headache, and decreased hemoglobin.
Tafenoquine
Debrisoquine
Amodiaquine
Piperaquine
Flumequine
Artemether
Mefloquine
Chloroquine